BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 19081614)

  • 21. A comprehensive strategy to address shortage of Erwinia asparaginase in pediatric acute lymphoblastic leukemia.
    Vagrecha A; Tao V; Corless R; Colon C; Redner A; Atlas M
    Expert Rev Clin Pharmacol; 2023; 16(8):763-769. PubMed ID: 37294084
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment.
    Müller HJ; Beier R; Löning L; Blütters-Sawatzki R; Dörffel W; Maass E; Müller-Weihrich S; Scheel-Walter HG; Scherer F; Stahnke K; Schrappe M; Horn A; Lümkemann K; Boos J
    Br J Haematol; 2001 Sep; 114(4):794-9. PubMed ID: 11564065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia.
    Woo MH; Hak LJ; Storm MC; Evans WE; Sandlund JT; Rivera GK; Wang B; Pui CH; Relling MV
    Leukemia; 1998 Oct; 12(10):1527-33. PubMed ID: 9766495
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
    Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP
    Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypersensitivity to Pegylated E.coli asparaginase as first-line treatment in contemporary paediatric acute lymphoblastic leukaemia protocols: a meta-analysis of the Ponte di Legno Toxicity working group.
    Brigitha LJ; Fiocco M; Pieters R; Albertsen BK; Escherich G; Lopez-Lopez E; Mondelaers V; Vora A; Vrooman L; Schmiegelow K; van der Sluis IM;
    Eur J Cancer; 2022 Feb; 162():65-75. PubMed ID: 34954438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia.
    Vrooman LM; Supko JG; Neuberg DS; Asselin BL; Athale UH; Clavell L; Kelly KM; Laverdière C; Michon B; Schorin M; Cohen HJ; Sallan SE; Silverman LB
    Pediatr Blood Cancer; 2010 Feb; 54(2):199-205. PubMed ID: 19672973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia.
    Vrooman LM; Kirov II; Dreyer ZE; Kelly M; Hijiya N; Brown P; Drachtman RA; Messinger YH; Ritchey AK; Hale GA; Maloney K; Lu Y; Plourde PV; Silverman LB
    Pediatr Blood Cancer; 2016 Feb; 63(2):228-33. PubMed ID: 26376459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Asparaginase Erwinia chrysanthemi as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia who have developed hypersensitivity to E. coli-derived asparaginase.
    Figueiredo L; Cole PD; Drachtman RA
    Expert Rev Hematol; 2016 Mar; 9(3):227-34. PubMed ID: 26765930
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of anti-asparaginase antibodies during therapy with E.coli asparaginase in children with newly diagnosed acute lymphoblastic leukemia and lymphoma.
    Ebeid EN; Kamel MM; Ali BA
    J Egypt Natl Canc Inst; 2008 Jun; 20(2):127-33. PubMed ID: 20029468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Asparaginase treatment in infants with acute lymphoblastic leukemia; pharmacokinetics and asparaginase hypersensitivity in Interfant-06.
    Albertsen BK; Harila-Saari A; Jahnukainen K; Lähteenmäki P; Riikonen P; Möttönen M; Lausen B
    Leuk Lymphoma; 2019 Jun; 60(6):1469-1475. PubMed ID: 30632847
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Managing hypersensitivity to asparaginase in pediatrics, adolescents, and young adults.
    Shinnick SE; Browning ML; Koontz SE
    J Pediatr Oncol Nurs; 2013; 30(2):63-77. PubMed ID: 23380527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia.
    Woo MH; Hak LJ; Storm MC; Sandlund JT; Ribeiro RC; Rivera GK; Rubnitz JE; Harrison PL; Wang B; Evans WE; Pui CH; Relling MV
    J Clin Oncol; 2000 Apr; 18(7):1525-32. PubMed ID: 10735901
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of hypersensitivity reactions to cancer chemotherapeutic agents in pediatric patients.
    Turgay Yagmur I; Guzelkucuk Z; Yarali N; Ozyoruk D; Toyran M; Civelek E; Ozbek NY; Dibek Misirlioglu E
    Ann Allergy Asthma Immunol; 2020 Apr; 124(4):350-356. PubMed ID: 31981613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Silent hypersensitivity to Escherichia coli asparaginase in children with acute lymphoblastic leukemia.
    Strullu M; Corradini N; Audrain M; Orsonneau JL; Bouige D; Thomare P; Vermot-Desroches C; Mansuy A; Legrand A; Rozé JC; Mohty M; Méchinaud F
    Leuk Lymphoma; 2010 Aug; 51(8):1464-72. PubMed ID: 20545581
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia.
    Ettinger LJ; Kurtzberg J; Voûte PA; Jürgens H; Halpern SL
    Cancer; 1995 Mar; 75(5):1176-81. PubMed ID: 7850718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypersensitivity reactions to asparaginase therapy in acute lymphoblastic leukemia: immunology and clinical consequences.
    Burke MJ; Zalewska-Szewczyk B
    Future Oncol; 2022 Mar; 18(10):1285-1299. PubMed ID: 35107320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Asparaginase Erwinia chrysanthemi (Erwinaze®): a guide to its use in acute lymphoblastic leukemia in the USA.
    Keating GM
    BioDrugs; 2013 Aug; 27(4):413-8. PubMed ID: 23794007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Incidence of Hypersensitivity Reactions to Pegylated Asparaginase in Children With Acute Lymphoblastic Leukemia: A City-wide Experience.
    Alrazzak M; Beaupin LK; Kinyoun P; Barth M
    J Pediatr Hematol Oncol; 2016 Jan; 38(1):e16-20. PubMed ID: 26558809
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative pharmacokinetic studies of three asparaginase preparations.
    Asselin BL; Whitin JC; Coppola DJ; Rupp IP; Sallan SE; Cohen HJ
    J Clin Oncol; 1993 Sep; 11(9):1780-6. PubMed ID: 8355045
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peg-asparaginase for acute lymphoblastic leukemia.
    Rytting M
    Expert Opin Biol Ther; 2010 May; 10(5):833-9. PubMed ID: 20345338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.